Ibio, INC 8-K filings

iBio announced its fiscal first quarter 2025 financial results, highlighting progress in its myostatin program and a decrease in operating expenses.

iBio, Inc. has updated its corporate presentation, highlighting its shift towards a machine-learning enabled antibody discovery platform and a growing pipeline in immuno-oncology and cardiometabolic diseases.

iBio, Inc. announced its fiscal year 2024 financial results, showcasing progress in its AI-driven antibody platform, strategic collaborations, and significant debt reduction.

iBio, Inc. has amended its employment agreement with CEO Martin Brenner, increasing his base salary and potential bonus, effective July 1, 2024.

iBio, Inc. has updated its equity award agreements and code of business conduct and ethics to better align with current practices and facilitate equity grants.

iBio Inc. has entered into an agreement to sell up to $7.35 million of its common stock through an at-the-market offering.

iBio, Inc. has finalized the sale of its Texas manufacturing facility for $8.5 million, eliminating $13.2 million in secured debt and marking its transition to an AI-driven biologics company.

iBio is leveraging its proprietary machine learning antibody engine to develop first-in-class and best-in-class drugs, focusing on immuno-oncology and expanding into cardiometabolic diseases.

iBio, Inc. subsidiary iBio CDMO LLC has agreed to sell its Texas facility for $8.5 million and settle its debt with Woodforest National Bank through a combination of cash and a pre-funded warrant.

iBio announced its fiscal third quarter 2024 financial results, showcasing a strategic collaboration with AstralBio and a strengthened cash position following a recent equity financing.

iBio, Inc. has successfully completed a private placement, raising approximately $15.1 million to support research and development and extend its operational funding.

iBio has sold its early-stage PD-1 agonist program to Otsuka Pharmaceutical for an upfront payment of $1 million, with potential for up to $52.5 million in milestone payments.

iBio, Inc. has engaged Grassi & Co. as its new independent auditor for the fiscal year ending June 30, 2024, following the resignation of CohnReznick LLP.

iBio, Inc. has entered into a credit and security agreement for a $1.07 million term loan to support its operations, secured by company assets.